Table 1

Clinical characteristics of the patients

Patient IDAge/genderCancerPrevious chemotherapyTNM cancer stagingICI (number of cycles)irAEs (grade)TreatmentsClinical resolution
Patient 177/FMerkel carcinomaNoStade IIAPembrolizumab (six cycles)Myocarditis G2
Pericarditis
NoneYes
Patient 279.6/MMelanomaNoStage IVFirst line: pembrolizumab (two cycles) Second line: ipilimumab and nivolumab (three cycles)Myocarditis G3
Ocular myositis
CS+infliximabYes
Patient 364.9/MMelanomaNoStage IIICPembrolizumab (two cycles)Myocarditis (G3)
Hepatitis (G3)
Myositis (G2)
CS+MMF+infliximabYes
Patient 457.7/MSmall cell neuro-endocrine carcinomaCisplatine–etoposideStage IIIBIpilimumab and nivolumab (two cycles)Myocarditis (G3–G4)
Ocular myositis
CS+TCZYes
Patient 566.3/MProstate adenocarcinomaTaxotere and cabazitaxelStage IVNivolumab
(one cycle)
Myocarditis (G3–G4)
Myositis
CS+MMF+TCZYes
Patient 664.9/MSquamous cell anal carcinomaCapecitabine–mytomycinRecurrence (LNPembrolizumab (two cycles)Myocarditis (G3)
Hepatitis (G2)
Myositis (G3)
CSYes
Patient 784.6/MMelanomaNoStage IVNivolumab (four cycles)Myocarditis (G2)
Myositis
CSYes
Patient 887.7/MMelanomaNoStage IVFirst line: pembrolizumab (two cycles)
Second line: ipilimumab and nivolumab
(two cycles)
Myocarditis (G3–G4)
Myositis
CS+TCZYes
Patient 974.9/MHepatocellular carcinomaNoStage IVAtezolizumab (four cycles)Myocarditis (G2)
Myositis
CSYes
Patient 1056/MMelanomaNoStage IVIpilimumab and nivolumab (four cycles)Myocarditis (G1)
Colitis (G3)
Acute interstitial nephritis
CS+infliximab+TCZYes
Patient 1164.6/MMelanomaNoStage IIICFirst line: nivolumab (16 cycles)
Second line: ipilimumab and nivolumab (four cycles)
Myocarditis (G1)
Colitis (G3)
Thyroiditis
Hypophysitis
CS+infliximabYes
  • CS, corticosteroid; F, female; ICI, immune checkpoint inhibitor; irAE, immune-related adverse event; LN, lymph node; M, male; MMF, mycophenolate mofetil; TCZ, tocilizumab; TNM, tumour, node, metastasis.